Tesamorelin Acetate
| Attribute | Detail |
|---|---|
| Catalog No. | [Insert Product Number Here] |
| Purity | >98% (Third-Party Tested HPLC/MS) |
| Form | Lyophilized Powder |
| Quantity | 2mg or 5mg [Select appropriate size] |
| CAS Number | 126118-97-8 |
⚠️ FOR LABORATORY RESEARCH USE ONLY ⚠️
This product is a research chemical intended strictly for in vitro and ex vivo laboratory experimentation. It is explicitly labeled "Not For Human Consumption."
Product Description
Tesamorelin (also known as Egrifta) is a synthetic peptide consisting of 44 amino acids. It is an analogue of growth hormone-releasing hormone (GHRH) and functions as a GHRH secretagogue. In a clinical context (when approved for specific medical use), Tesamorelin stimulates the pituitary gland to release endogenous growth hormone (GH).
Scientific Research Applications
Tesamorelin is a subject of significant interest in metabolic and endocrinology research. While the pharmaceutical version Egrifta has specific FDA approval for treating HIV-associated lipodystrophy (abnormal fat distribution), the research chemical is used in experimental settings to study the mechanisms of:
- Growth Hormone Dynamics: Researchers utilize Tesamorelin to explore how stimulating the natural GHRH receptor affects the production and dynamics of endogenous growth hormone and IGF-1 in research models.
- Metabolic Studies: Investigations focus on the peptide's role in lipid metabolism and body composition in experimental subjects, specifically how it influences visceral adipose tissue.
- Cardiovascular Health Research: Preclinical and clinical studies in a therapeutic context have also explored its potential effects on cardiovascular risk markers in specific populations.
Technical Specifications
- Sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- Molecular Formula: C221H366N72O67S1
- Storage: Store lyophilized powder at 2°C - 8°C. Upon reconstitution, store at 2°C - 8°C and use within [insert relevant timeframe, e.g., 8 days]. Protect from light.
Important Regulatory & Safety Information
- Unapproved for General Use: This is a research chemical. The prescription drug formulation of Tesamorelin (Egrifta) is FDA-approved only for a specific medical condition (HIV-associated lipodystrophy) and must be administered under medical supervision. This product is not intended to treat, cure, or prevent any disease.
- No Human Use Data for this formulation: Safety and efficacy have not been established for general human use.
- Purchaser Responsibility: By purchasing this product, the buyer acknowledges that they are a qualified researcher and assumes all liability for the use and handling of this research chemical. You must comply with all applicable laws and regulations in your jurisdiction.